RVX THERAPEUTICS INC has a total of 11 patent applications. Its first patent ever was published in 2004. It filed its patents most often in WIPO (World Intellectual Property Organization), China and Canada. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and environmental technology are INVEST Y NUTRICION S L, OPKO HEALTH INC and CMG PHARMACEUTICAL CO LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 6 | |
#2 | China | 2 | |
#3 | Canada | 1 | |
#4 | EPO (European Patent Office) | 1 | |
#5 | Hong Kong | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Environmental technology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Heterocyclic compounds | |
#4 | Climate change adaptation technologies |
# | Name | Total Patents |
---|---|---|
#1 | Young Peter Ronald | 7 |
#2 | Martin Gregory Scott | 4 |
#3 | Duffy Bryan Cordell | 4 |
#4 | Quinn John Frederick | 4 |
#5 | Lebioda Kenneth | 3 |
#6 | Mclure Kevin G | 3 |
#7 | Wong Norman C W | 3 |
#8 | Liu Shuang | 3 |
#9 | Mihara Koichiro | 3 |
#10 | Tucker Joe | 3 |
Publication | Filing date | Title |
---|---|---|
CN105073744A | Novel heterocyclic compounds as bromodomain inhibitors | |
WO2014080291A2 | Biaryl derivatives as bromodomain inhibitors | |
WO2014080290A2 | Cyclic amines as bromodomain inhibitors | |
WO2013186612A1 | The use of substituted 2-phenyl-3h-quinazolin-4-ones and analogs for inhibiting bet (bromodomain and extra terminal domain) proteins | |
WO2013156869A1 | Treatment of diseases by epigenetic regulation | |
WO2013175281A1 | Use of substituted 2-phenyl-3h-quinazolin-4-ones and analogs for inhibiting bromodomain and extra terminal domain (bet) proteins | |
CN1852741A | Compounds and methods for downregulating the effects of TGF-beta |